PMID- 16730380
OWN - NLM
STAT- MEDLINE
DCOM- 20060929
LR  - 20061115
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 176
IP  - 1-2
DP  - 2006 Jul
TI  - Intravenous immunoglobulin suppresses experimental myasthenia gravis: 
      immunological mechanisms.
PG  - 187-97
AB  - Intravenous immunoglobulin (IVIG) administration has been beneficially used in 
      the treatment of several autoimmune disorders including myasthenia gravis (MG), 
      although its mechanism of action is still not clear. To study the optimal 
      conditions of IVIG treatment and delineate its mechanism of action we established 
      a suitable model in rat experimental autoimmune MG (EAMG). We show that IVIG has 
      a suppressive effect on the clinical symptoms of ongoing EAMG that is associated 
      with decreased AChR-specific cellular and humoral immune reactivity. 
      Costimulatory factors and cytokine profile analyses suggest that IVIG 
      immunomodulation in EAMG involves suppression of B and Th1-type T cell responses 
      with no generation of T-regulatory cells. Our data contribute to the 
      understanding of the immunological mechanisms underlying IVIG treatment in MG and 
      in other autoimmune disorders.
FAU - Zhu, Kai-Yun
AU  - Zhu KY
AD  - Department of Immunology, Weizmann Institute of Science, Rehovot 76100, Israel.
FAU - Feferman, Tali
AU  - Feferman T
FAU - Maiti, Prasanta K
AU  - Maiti PK
FAU - Souroujon, Miriam C
AU  - Souroujon MC
FAU - Fuchs, Sara
AU  - Fuchs S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060526
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Cholinergic)
RN  - 0 (Receptors, Interleukin-2)
RN  - 0 (Transforming Growth Factor beta)
RN  - 130068-27-8 (Interleukin-10)
RN  - 207137-56-2 (Interleukin-4)
SB  - IM
MH  - Animals
MH  - Female
MH  - Immunoglobulin G/blood/classification
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Interleukin-10/physiology
MH  - Interleukin-4/physiology
MH  - Lymphocyte Activation
MH  - Myasthenia Gravis, Autoimmune, Experimental/immunology/*prevention & control
MH  - RNA, Messenger/analysis
MH  - Rats
MH  - Rats, Inbred Lew
MH  - Receptors, Cholinergic/immunology
MH  - Receptors, Interleukin-2/genetics
MH  - Transforming Growth Factor beta/genetics
EDAT- 2006/05/30 09:00
MHDA- 2006/09/30 09:00
CRDT- 2006/05/30 09:00
PHST- 2006/01/24 00:00 [received]
PHST- 2006/03/21 00:00 [revised]
PHST- 2006/04/10 00:00 [accepted]
PHST- 2006/05/30 09:00 [pubmed]
PHST- 2006/09/30 09:00 [medline]
PHST- 2006/05/30 09:00 [entrez]
AID - S0165-5728(06)00143-3 [pii]
AID - 10.1016/j.jneuroim.2006.04.011 [doi]
PST - ppublish
SO  - J Neuroimmunol. 2006 Jul;176(1-2):187-97. doi: 10.1016/j.jneuroim.2006.04.011. 
      Epub 2006 May 26.